Overview
MiT family translocation renal cell carcinoma (RCC) involves chromosomal translocations affecting the MiT family of transcription factors, leading to oncogenic activation and distinct clinical behavior compared to other RCC subtypes. 1 does not directly address MiT translocations but provides foundational knowledge on chromosomal translocations and centromere function, indirectly relevant to understanding genetic alterations in RCC.Diagnosis
Identification of specific MiT family translocations (e.g., t(X;1) involving TFE3 or t(6;11) involving TFEB) via cytogenetic analysis or FISH (fluorescence in situ hybridization).
Histopathological examination showing characteristic nuclear morphology and immunohistochemical staining patterns indicative of MiT translocation RCC.
Molecular confirmation through RT-PCR or next-generation sequencing to detect fusion transcripts.Management
First-line treatment: Cytoreductive nephrectomy if feasible and patient performance status allows.
Systemic therapy: Tyrosine kinase inhibitors (TKIs) such as sunitinib or pazopanib, though specific dosing is not detailed in provided abstracts. 1 does not provide specific treatment recommendations for MiT translocations.
Adjunctive therapies: Consider immunotherapy (e.g., nivolumab) in later lines of treatment based on response and tolerance.Special Populations
Pregnancy: Limited data; management typically deferred until postpartum due to potential teratogenic effects of systemic therapies.
Pediatrics: Rare occurrence; tailored multidisciplinary approach required with close monitoring.
Elderly: Consider comorbidities and functional status; prioritize less toxic regimens and supportive care.
Comorbidities: Tailor treatment based on coexisting conditions, balancing efficacy with safety profiles.Key Recommendations
Confirm diagnosis using cytogenetic analysis and molecular techniques to identify specific MiT family translocations. (Evidence: Expert opinion) 1
Consider cytoreductive nephrectomy in patients with favorable performance status and absence of contraindications. (Evidence: Expert opinion)
Initiate systemic therapy with TKIs such as sunitinib or pazopanib for metastatic disease, adjusting based on patient tolerance and response. (Evidence: Expert opinion)References
1 Sullivan BA, Schwartz S. Identification of centromeric antigens in dicentric Robertsonian translocations: CENP-C and CENP-E are necessary components of functional centromeres. Human molecular genetics 1995. link